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Background: Human umbilical cord blood derived-mesenchymal stem cells (hUCMSCs) offer an attractive alternative
to bone marrow-derived MSCs (BMMSCs) for cell-based therapy as it is a less invasive source of biological material.
However, limited studies have been conducted with hUCMSCs as compared to BMMSCs. The present study was
conducted to evaluate the effects of hUCMSCs in esophageal carcinoma (EC).
Methods: hUCMSCs together with EC cells were transplanted subcutaneously into BALB/c nude mice to observe
the effects of hUCMSCs on tumor establishment. hUCMSCs injected through the caudal vein to the mice with
pre-established EC to observe the effects of hUCMSCs on tumor outgrowth. In order to elucidate the underlying
mechanisms, we also performed in vitro experiments including directly co-culture, transwell assay, proliferation assay
and western blotting analysis.
Results: hUCMSCs promoted EC formation in nude mice. In the in vivo model of pre-established EC, intravenously
injected hUCMSCs potently promoted tumor growth. When in vitro co-cultured with hUCMSCs, EC cells proliferation
increased. After co-cultured with hUCMSCs through transwell system, EC cells showed increased proliferation. Through
transwell assay, we also observed that EC cells recruited MSCs, and MSCs promoted EC cells migration and invasion.
Western blotting data showed that the expressions of proliferation related proteins Bcl-2, survivin and metastasis related
proteins MMP-2 and MMP-9 were up-regulated in the EC cells transwell co-cultured with hUCMSCs.
Conclusions: Our results indicated that hUCMSCs could favor tumor growth in vivo and in vitro. Thus, the exploitation
of hUCMSCs in new therapeutic strategies should be cautious under the malignant conditions.
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Mesenchymal stem cells (MSCs) were first identified by
Friedenstein and were described as an adherent, fibroblast-
like population in the in vitro culture of bone marrow,
which were also found to be able to differentiate into bone
in vivo [1] Subsequently, the concept expanded, it proved
that MSCs are not only bone marrow resident cells but are
also found in many other tissues of the body including adi-
pose, umbilical cord, fetal liver, muscle and lung [2-4].
MSCs possess an innate ability for self-renewal and can* Correspondence: shuxueke12@gmail.com
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unless otherwise stated.differentiate into multiple cell types, such as osteocytes, ad-
ipocytes, chondrocytes, myocytes, cardiomyocytes, fibro-
blasts, myofibroblasts, epithelial cells, and neurons [5].
Accumulating studies of the past few years support their
use for treating both genetic and acquired human diseases
associated to loss of specialized tissues [6,7]. In addition,
MSCs have received intensive attention in the field of tu-
mors. Tumor tissue contains abundant growth factors, cy-
tokines and matrix-remodeling proteins, explaining why
tumors are likened to wounds that never heal [8]. It has
been reported that MSCs migrate to a variety of tumors,
this migratory ability points to MSCs as attractive candi-
dates for delivery vehicles of antitumor agents [9,10].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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revealed that MSCs promote tumor growth and metastasis
[11,12] which would present a serious obstacle to using
MSCs as delivery vehicles for anti-cancer therapy. But prior
studies on the biology and therapeutic application of human
MSCs in human malignancies have reported mixed results.
MSCs injected intravenously in a mouse model of Kaposi’s
sarcoma were shown to home to sites of tumorigenesis and
potently inhibit tumor growth [13]. MSCs have also been
shown to have anti-angiogenic effect both in vitro and in
mouse models of melanoma [14]. The inconsistent results
are clear indicators that the effect of MSCs on tumor cells is
poorly understood and need further investigation.
Mesenchymal stem cells used in the experiment are
mostly acquired from adult BM. Wharton’s jelly (WJ) of
the umbilical cord exhibits the characteristics of stromal
cells and is a novel source of mesenchymal stem cells
[15]. Mesenchymal stem cells that are derived from WJ
of human umbilical cord (hUCMSCs) have been shown
to evidence characteristics similar to those of bone
marrow stromal cells (BMSCs). Compared to BMMSCs,
UCMSCs have many advantages to use in cell-based
therapy because of their relatively large ex vivo expan-
sion capacity, low risk of viral infection, lack of donor
morbidity, and less pronounced immunogenicity [16-18].
So, it offers an attractive alternative to BMSCs for cell-
based therapy. However, the MSCs used in the founda-
tion researches and clinical experiments are mostly
acquired from adult BM. Though similarly, there were
evidence showed that hUCMSCs have unique properties
compared to BMMSCs [19]. However, there is little data
on the relationship between hUCMSCs and tumors.
To explore the role of hUCMSCs on tumors, we stud-
ied the effects of human hUCMSCs on the esophageal
carcinoma (EC) because it occurs with high prevalence
in many areas of the world especially in China [20,21].
We investigated the influence of hUCMSCs on EC
growth in vivo. We also investigate in vitro co-culture of
two different types of EC cell lines with hUCMSCs to
explore the mechanism that how hUCMSCs affected
tumor growth.
Results
Characteristics of hUCMSCs derived from human
umbilical cord
The isolated clonogenic hUCMSCs were analyzed by the
flow cytometry analysis and gated for granularity, size
and surface markers. The gated cells were analyzed for
the expression of cell membrane proteins markers and
found to be negative for the expression of hematopoietic
markers such as CD45, CD14, CD19 and also HLA-DR
(MHC II) and CD34 (endothelial/hematopoietic stem
cell markers), but were positive for CD29, CD44, CD73,
CD90 and CD105, which are generally considered formarkers of mesenchymal stem cells (Figure 1A). These
observations demonstrate that cells that are isolated
from WJ of the human umbilical cord have the same
surface markers as BMMSCs. The cultured cells were
also tested for their potential to differentiate into osteo-
genic or adipogenic cells prior to use. The effectiveness
of osteogenic differentiation was confirmed by histo-
chemical staining for the identification of Ca2+ crystals
by Alizarin Red staining (Figure 1B). The effectiveness of
adipogenic differentiation was confirmed by histochem-
ical staining for the identification of neutral lipid vacu-
oles by Oil red O staining (Figure 1C). Thus, the isolated
cells met the essential criteria used to define MSCs.
hUCMSCs favor esophageal cancer growth in vivo
To assess the effect of hUCMSCs on esophageal cancer
formation in vivo, human esophageal squamous cancer
cells (Eca109 cell line, 5 × 106 per mouse) were injected
subcutaneously into the Armpit region of nude mice
alone or mixed with hUCMSCs (5 × 106 per mouse). All
of the mice developed growing tumors at the injection
sites, and the mice that had received injections of
Eca109 and hUCMSCs mixed cells (marked as Eca109 +
hUCMSCs group, n = 5) developed bigger tumors than
that were observed in the mice injected solely with can-
cer cells (Eca109 group, n = 5) (Figure 2A). This observa-
tion implied that hUCMSCs could promote esophageal
cancer formation in nude mice. Because tumor establish-
ment and subsequent tumor growth are distinct bio-
logical processes, we sought to determine whether
hUCMSCs exerted similar effects in animals with pre-
established esophageal tumors. To test this, 5 × 106
Eca109 cells were inoculated in the right Armpit on day
0. Palpable tumors were appreciated in all animals by
day 20. A subset of animals was then injected with 5 ×
106 hUCMSCs on days 20, 25, and 30 through their
caudal vein. These mice were marked as Eca109, iv
hUCMSCs group (n = 6). After injection of exogenous
hUCMSCs through the caudal vein, the volume of tumor
was measured at four-day intervals until sacrifice of the
animal. Enhanced tumor volume was observed from
day16 after injection of hUCMSCs. (p < 0.05) (Figure 2B).
We also found that tumors formed by Eca109 cells
admixed with hUCMSCs also increased in blood vessel
formation in gross analysis, compared with tumors formed
by Eca109 alone (Figure 2C).
Taken together, these observations implied that the
formation and development of esophageal cancer were
promoted in response to exogenous hUCMSCs.
Increase in the number of lymph node metastases by
injection of Eca109 cells mixed with hUCMSCs
The 16 mice are all alive on day 44. Surviving nude mice
were killed. The ipsilateral and contralateral axillary lymph
Figure 1 Characteristics of hUCMSCs derived from human umbilical cord. (A) Flow cytometric histograms showing the immunophenotype
of umbilical vein mesenchymal stem cells. The cells were analyzed by their physical parameters: granularity and size. The gated cells were
negative for the hematopoietic line markers CD45, CD14, CD19 and for HLA-DR and CD34. Analyzed cells were positive for CD29, CD73, CD90,
CD44 and CD105, which are considered to be markers of mesenchymal stem cells. Isotype controls show non-specific fluorescence. (B) HUCMSCs
differentiate into osteoblasts. Calcium deposition, indicative of osteoblasts, was stained with Alizarin Red stain. (C) HUCMSCs differentiate into
adipocytes. The presence of triglycerides, characteristic of adipocytes, was revealed by staining with oil red O.
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Figure 2 hUCMSCs favor esophageal cancer growth in vivo. (A) HUCMSCs promoted the esophageal tumors formation in nude mice. The
results were expressed as mean ± S.D. *P < 0.05, Eca109 + hUCMSCs versus Eca109. (B) HUCMSCs promoted the pre-established esophageal
tumors growth in nude mice. *P < 0.05, Eca109, i.v. hUCMSCs versus Eca109. (C) On the 44th day after implantation, the mice were killed. Tumors
formed by Eca109 cells admixed with hUCMSCs increased in blood vessel formation in gross analysis. (D) Lymph node metastasis was seen in the
group that mixed Eca109 cells and hUCMSCs were injected.
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two ipsilateral axillary lymph nodes and two contralat-
eral axillary lymph nodes. After H&E staining, we found
2 lymph nodes metastases in the 20 lymph nodes of 5
mice that received mixed-cell (Figure 2D). In contrast,
lymphatic metastasis was not detected in the other two
groups of mice. This result indicated, in a manner, that
hUCMSCs enhanced lymph node metastasis of esopha-
geal carcinoma.
hUCMSCs promote the proliferation of tumor cells in vitro
To understand the mechanisms underlying the in vivo
promotion of tumor growth by the injected hUCMSCs,
we assessed the proliferation of esophageal squamous
cancer cells during their co-culture with hUCMSCs.
Considering that using only one esophageal squamous
cancer cell line had its limitations in supporting any
conclusion, we used two esophageal squamous cancer
cell lines, Eca109 and TE-1, in the following experi-
ments. When esophageal cancer cells were directly co-
cultured with hUCMSCs in a 24-well plate, the cells
proliferation increased significantly when compared withthe control group (Figure 3A). To investigate whether
hUCMSCs promote tumor cells proliferation through se-
creting soluble factors, a transwell assay that physically
separated hUCMSCs from tumor cells in co-culture sys-
tem was performed in parallel. Transwell system allows
for the effect of soluble factors, but prevents direct cell-
cell contact. The statistically significant difference was
observed between transwell co-culture group and the
control group (Figure 3B). The result suggested that
hUCMSCs could promote esophageal cancer cell prolif-
eration through the soluble factors they secrete.
Esophageal cancer cells attracted hUCMSCs in vitro
have the ability to attract hUCMSCs in vitro, migration
assay was performed. We found that more hUCMSCs
migrated toward the Eca109 or TE-1 cell culture than
toward the medium without esophageal cancer cells
(Figure 4). Co-cultured with Eca109 cells resulted in an
8.9 fold increased number of migrated cells compared
with the controls. Co-cultured with TE-1 cells resulted
in a 7.8 fold increased number of migrated hUCMSCs
compared with the controls.
Figure 3 Proliferation of esophageal cancer cells is promoted by hUCMSCs in vitro. (A) Esophageal cancer cells and hUCMSCs were
performed directly contacting co-culture. Before co-cultured with esophageal cancer cells, hUCMSCs were treated with mitomycin C (20 μg/ml)
to prevent cell proliferation. Then esophageal cancer cells were co-cultured with hUCMSCs for 48 hours. Separately cultured cancer cells and
mitomycin-treated hUCMSCs were used as control. (B) Eca109 and TE-1 cells were co-cultured with hUCMSCs by using the transwell co-culture
systems for 48 h, and then, cells were harvested for proliferation assays. The results are shown as mean ± SD of three independent experiments in
comparison with that of controls not co-cultured with hUCMSCs (*P < 0.05 versus control).
Figure 4 Esophageal cancer cells attract hUCMSCs in vitro. The migratory ability of hUCMSCs was analyzed by transwell assay. A significantly
greater number of hUCMSCs migrated toward the culture of esophageal cancer cells (Eca109 or TE-1) than toward the medium without
esophageal cancer cells. The number of cells was counted in five fields per Transwell membrane. Each group consisted of three duplicates.
(∗p < 0.05 versus control).
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and invasion in vitro
Migration and invasion of cancer cells is an essential step
of cancer metastasis. Since we found that hUCMSCs en-
hanced the lymph node metastasis of esophageal cancer,
the impact of hUCMSCs on esophageal cancer cell migra-
tion and invasion was further investigated using transwell
assay. Esophageal cancer cells (Eca109 and TE-1 cells)
co-cultured with hUCMSCs showed a relative higher abil-
ity of migration. Co-cultured with hUCMSCs resulted
in an increased number of migrated cells (2.3 fold for
Eca109 and 3.3 fold for TE-1) compared with the controls
(Figure 5A). In the invasion assay, esophageal cancer cells
were seeded into transwell millicell precoated with Matri-
gel which imitates the extracellular matrix. Cells migrating
through the matrix were stained. For Eca109 cells, the ra-
tio of cells invading through matrigel was 110% more in
hUCMSCs co-cultured cells than control cells. And co-
culturing with hUCMSCs increased TE-1 cells invasion by
220% (Figure 5B).
Molecular expression changes in esophageal cancer cells
co-cultured with hUCMSCs by transwell system
Bcl-2, Bax and survivin are molecules associated with
the proliferation and apoptosis of tumor cells. MMP-2
and MMP-9 are the important proteins associated with
tumor cells invasion characteristic. In order to find out
the molecular mechanism underlying the promotion ef-
fect of hUCMSCs on tumor cells in vitro, we investi-
gated the expressions of these proteins in tumor cells
by Real-time RT-PCR (Figure 6A) and Western blotting
(Figure 6B and C). The results showed that co-cultured
Eca109 cells with hUCMSCs by transwell chamber for
48 h resulted in the significant up-regulation of expres-
sion levels of Bcl-2, survivin, MMP-2 and MMP-9 as
compared to controls. TE-1 cells co-cultured with
hUCMSCs for 48 h resulted in increased Bcl-2, survivin
and MMP-2 protein levels as compared to controls.
Discussion
The aim of the current study was to study the inter-
action between hUCMSCs and esophageal carcinoma.
hUCMSCs were transplanted into BALB/c nude mice in
an effort to observe the outgrowth of the tumor. The re-
sults indicated that all of the groups into which mixed
cells were injected evidenced larger tumor size than the
groups injected solely with Eca109 cells, thereby indicat-
ing that hUCMSCs could favor esophageal tumor forma-
tion. Furthermore, we also found that in the mice with
pre-established esophageal carcinoma, i.v. injection of
hUCMSCs also promoted the tumor growth.
Multiple mechanisms may be responsible for the hUCMSCs
induced increase of tumorigenesis and tumor growths.
hUCMSCs have been shown to have immunmodulatoryaction in vivo and in vitro [22,23]. In this experiment,
we used nude mice for xenotransplantation. Therefore,
increased allogenic tolerance via co-injection with hUCMSCs
cannot provide a reasonable explanation for this phenomenon.
In this study, we offer two possible explanations for the
enhanced tumor growth in response to hUCMSCs. Firstly,
hUCMSCs directly stimulate the growth of esophageal
cancer cells. The findings of this study, namely that
the mixed culture or cultured by transwell system with
hUCMSCs increased the proliferation of esophageal can-
cer cells in vitro, indicated that hUCMSCs induce the in-
creased proliferation of transplanted tumor cells. It also
appears that the promoted effects of hUCMSCs on
esophageal carcinoma cells may be both cell-contact
dependent as well as mediated via diffusible factors se-
creted by the hUCMSCs. It was difficult to distinguish
tumor cells from hUCMSCs directly cocultured with
them, so we only detected the molecular changes in the
tumor cells induced by the hUCMSCs-transwell co-
culture. The in vitro molecular data showed that the in-
crease in the proliferation of tumor cells were associated
with the up-regulation of Bcl-2 and survivin expressions.
In vivo, we observed that tumors formed by Eca109
cells admixed with hUCMSCs increased in blood vessel
formation in gross analysis, compared with tumors
formed by Eca109 alone. Angiogenesis is critical for
tumor growth so that the blood vessel in the tumor en-
vironment could provide sufficient nutrients and oxygen
to the cells, which are essential for the growth and sur-
vival of tumor cells [24]. It is known that MSCs could
produce various growth factors that stimulate angiogen-
esis, [25] so it is possible that enhanced angiogenesis
may account for the esophageal tumor growth-
promoting effects by hUCMSCs.
In addition, we noticed that in the 20 axillary lymph
nodes of 5 mice received mixed-cell 2 lymph nodes metas-
tases were observed, but lymphatic metastasis was not de-
tected in the other two groups of mice. Our results from
in vitro assays showed that hUCMSCs promoted migra-
tion and invasion ability of esophageal carcinoma cells
in vitro. In our in vitro molecular experiment, MMP-2
and MMP-9 were found to be up regulated in EC cells co
cultured with hUCMSCs. Since MMP-2 and MMP-9 pro-
motes cell migration and invasion, [26,27] this may be
possible mechanism in which hUCMSCs promote esopha-
geal carcinoma cells invasion and thus may be a possible
explanation for hUCMSCs promoted the lymph node me-
tastasis of esophageal cancer.
In a paper published in 2010, Li’s results revealed
that hMSCs inhibited the proliferation and invasion
of Eca-109 cells in vitro [28]. It’ seems that their result is
quite different from ours. But the MSCs they investi-
gated were derived from bone marrow. The different
sources of MSCs for assessment may be one of the
Figure 5 hUCMSCs promotes migration and invasion of esophageal cancer cells in vitro. (A) Effects of hUCMSCs on esophageal cancer
cells migration. (B) Effects of hUCMSCs on esophageal cancer cells invasion. The number of cells was counted in five fields per Transwell
membrane. Each group consisted of three duplicates. (∗p < 0.05 versus control).
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tumorigenic or anti-tumorigenic effects. In agreement
with this, results of Akimoto’s study demonstrated that
umbilical cord blood-derived mesenchymal stem cells
inhibit, but adipose tissue-derived mesenchymal stem
cells promote glioblastoma multiforme proliferation
[29]. So, differences must be considered when choosing
a stem cell source for safety in clinical application.
Conclusions
hUCMSCs offers an attractive alternative to hBMMSCs
for cell-based therapy as it is a less invasive source ofbiological material. However, our results indicated that
hUCMSCs could favor esophageal carcinoma growth
in vitro and in nude mice model. There were a potential
limitation of our experimental designs, as the immune defi-
cient mice does not reflect the real conditions of human
beings, whether our results can be extrapolated to humans
requires further investigation. However, the data obtained
in this study still ringed alarm in using hUCMSCs as thera-
peutic application for humans in the future. So we sug-
gested that exploitation of hUCMSCs in new therapeutic
strategies should be cautious under the malignant condi-
tions, at least under the esophageal carcinoma condition.
Figure 6 Molecular changes in esophageal cancer cells co-cultured with hUCMSCs. The expressions of Bcl-2, Bax, survivin, MMP-2, MMP-9
in Eca109 cells or TE-1 cells were detected by qRT-PCR and Western blotting. Quantitative analysis showed that co-cultured Eca109 cells with
hUCMSCs by transwell chamber significantly increased mRNA (A) levels and protein (C) levels of Bcl-2, survivin, MMP-2 and MMP-9. TE-1 cells
co-cultured with hUCMSCs resulted in increased Bcl-2, survivin and MMP-2 mRNA (A) levels and protein (C) levels as compared to controls.
(B) Representative Western blotting images. The results were the means ± SD of three independent experiments (*P < 0.05 versus control).
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Cell culture
The human esophageal cancer cell lines Eca109 and TE-1
was purchased from the Cell Bank of the Chinese Acad-
emy of Sciences (Shanghai, China), where they were char-
acterized by mycoplasma detection, DNA-Fingerprinting,
isozyme detection and cell vitality detection. The cell lines
were maintained in culture as an adherent monolayer in
RPMI-1640 (GIBCO) medium supplemented with 10%
FBS. All cells were incubated at 37°C in 5% CO2 humidi-
fied cell culture incubator.
hUCMSCs preparation
Human umbilical cord samples were collected from 8
healthy donors. Written informed consent was obtained
from the pregnant women before labor. The umbilical cord
samples were collected in sterile boxes that contained PBS
solution. The collected human umbilical cord tissues were
washed three times with Ca2+ and Mg2 + −free PBS. They
were mechanically cut by scissors in a midline direction
and the vessels of the umbilical artery, vein and outlining
membrane were dissociated from the WJ. The jelly was
then extensively cut into pieces smaller than 0.5 cm3. The
explants then were cultured in DMEM/F12 (1:1) contain-
ing 10% fetal calf serum (FCS). They were left undisturbed
for five to seven days to allow for migration of the cells
from the explants. The cellular morphology became homo-
genously spindle-shaped in cultures after 4–8 passages.
HUCMSCs identification
The ability of MSCs to differentiate into osteoblasts and
adipocytes was confirmed prior to use. Osteogenicdifferentiation was evaluated by calcium deposition
staining using the Alizarin Red staining. The induction
of adipogenic differentiation was apparent by intracellu-
lar accumulation of lipid-rich vacuoles that stained with
Oil Red O. The specific surface molecules of HUCMSCs
were characterized by flow cytometric analysis. The
cells were stained with the following antibodies: CD14-
FITC, CD19-ECD, CD29-FITC, CD34-PE, CD44-FITC,
CD45-FITC, CD73-PE, CD90-FITC, CD105-PE, HLA-
DR-FITC (BD Pharmingen, USA). Thereafter, the cells
were analyzed using a Becton Dickinson flow cytometer
(Becton Dickinson, San Jose, CA).
Animal experiments
36 female BALB/c nude mice (4-week-old) were purchased
from the Beijing HFK Bioscience CO., LTD. Animals used
in this study were maintained in accordance with the Pol-
icy of Animal Care and Use Committee of Bethune Inter-
national Peace Hospital. Animals were housed in micro-
isolator cages under sterile conditions and observed for at
least 1 week to ensure proper health before study initiation.
Animals were injected with 5 × 106 Eca109 cells alone or
mixed with an equal number of hUCMSCs, subcutane-
ously into the Armpit region. Treatment with hUCMSCs
was also conducted in animals with pre-established tumors
by i.v. tail vein injection at a dose of 5 × 106 per mouse. In
some experiments, mice were given additional doses of
hUCMSCs by tail vein injection. Tumor growth and pro-
gression were monitored by every four days measurements
of tumors with calipers. The volume of tumor was calcu-
lated by using the following equation as reported previ-
ously [30]: volume = Length ×Width2/2.
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At the indicated time points, the animals were sacrificed.
After which tumors were dissected out. The ipsilateral
and contralateral axillary lymph nodes of the nude mice
were also collected. Then the tumor tissues and the
lymph nodes were fixed in 10% formaldehyde and proc-
essed using standard methods. The sections were stained
using hematoxylin and eosin (H&E) in order to examine
the histopathology.
Cell migration and invasion experiment
For the invasion assay, 24 well Transwell chambers
(8.0 μm pore, Corning, USA) were coated with a 50 μl
Matrigel (BD, Franklin Lakes). For migration assays, the
ECMgel was not needed. Tumor cells were cultured for
24 h in the mixture of tumor cell culture medium and
hUCMSCs-conditioned medium (1:1), and in control
groups tumor cells were cultured for 24 h in the tumor
cell culture medium supplemented with 50% DMEM/
F12 (1:1) medium, and then tumor cells were collected
and resuspended in the FBS-free RPMI 1640 medium at
a concentration of 5 × 105 cell per ml by cell counting
for three times. Then, the cell suspensions were put into
the upper compartment of the transwell chambers
(200 μl/well), and hUCMSCs (5000/well) was put into
the lower compartment. After cultured for 24 h, the cells
that did not penetrate the polycarbonate membrane at
the bottom of the chamber were wiped off with cotton
stickers. The membrane was removed and fixed with
methanol and stained with Crystal Violet. Five vision
fields were randomly selected under microscope and the
number of cells that penetrated the membrane was
counted. Each group consisted of three duplicates.
The migratory ability of hUCMSCs was also assayed
by means of a 24-well microchamber plate with un-
coated inserts (8.0 μm pore). Either 2.0 × 104 Eca109 or
TE-1 cells in DMEM with 0.5% FBS or medium alone
was plated into the lower chambers. After 4 hours of in-
cubation at 37°C, upper chambers containing 2.0 × 104
hUCMSCs in DMEM were set into the lower chambers.
Three wells were used for each experiment. After
16 hours of incubation, inserts were fixed with methanol
and stained with Crystal Violet. The number of migrat-
ing cells was determined as described above.
Cells co-culture and measurement of cell proliferation
Esophageal cancer cells (Eca109 or TE-1 cells) were cul-
tured either in directly contacting co-cultured or in in-
directly co-cultured (transwell system) with hUCMSCs.
Esophageal cancer cells and hUCMSCs directly contact-
ing co-cultured was performed as follow: hUCMSCs
were first seeded into 24 well plates (5 × 104/ml, 500ul/
well). Following 24 hours of incubation, hUCMSCs were
found tight attached to the bottom of the well. Beforeco-cultured with esophageal cancer cells, hUCMSCs
were treated with mitomycin C (20 μg/ml) to prevent
cell proliferation. Then esophageal cancer cells (5 × 104/
ml, 500ul/well) were added to the 24 well plates and co-
cultured with hUCMSCs at 37°C for 48 hours. Separately
cultured cancer cells and mitomycin-treated hUCMSCs
were used as control. Then cell proliferation was deter-
mined by Cell Counting Kit-8 (CCK-8, Dojindo, Japan),
which allows sensitive colorimetric assays for the deter-
mination of the number of viable cells. Before CCK-8
assay, the co-cultured cells and control group cells were de-
tached from the plates. Because the cancer cells can’t easily
separated from direct contact co-cultured hUCMSCs, the
separately cultured hUCMSCs and cancer cells were put to-
gether as controls.
In transwell system, hUCMSCs were physically sepa-
rated from esophageal cancer cells by a transwell mem-
brane with 0.4-μm pore size (Corning, USA.). hUCMSCs
were seeded on upper chamber of 24 well stranswell
plate and Eca109 or TE-1 cells were seeded on the lower
chamber of transwell plate. The cells were co-cultured
for 48 hours. The proliferation of cancer cells was
assessed by CCK-8 kit (Dojindo, Japan).
Every group had five wells. All the proliferation experi-
ments were run in triplicate and the results expressed as
mean ± SD.
Real-time RT-PCR
Quantitative PCR was performed using the SYBR Green
realtime PCR method. Esophageal cancer cells and
hUCMSCs were co-cultured by transwell system for
48 hours. Then, hUCMSCs were collected. Total RNA
was isolated from hUCMSCs using an Rneasy Mini Kit
(Qiagen, Valencia, CA, USA) and Trizol Reagent (Invi-
trogen). Quantitative RT-PCR was performed using an
ABI 7000 PCR instrument (Applied Biosystems, Foster
City, CA, USA). Each sample was tested in triplicate,
and the samples obtained from three independent exper-
iments were used for the analysis of relative gene expres-
sion using the 2−△△Ct method. The following primers
were used for real-time PCR:
human β-actin, F 5′-cctcgcctttgccgatcc-3′, R 5′-ggatcttc
atgaggtagtcagtc-3′;
human survivin, F 5′-agccctttcaaggaccac-3′, R 5′-gcactttc
ttcgcagtttcc-3′;
human Bcl-2, F 5′-tggccagggtcagagttaaa-3′, R 5′-tggcctc
tcttgcggagta-3′;
human Bax, F 5′-ttgcttcagggtttcatcca-3′,R 5′-agacactcgc
tcagcttcttg-3′;
human MMP-2, F 5′-tctcctgacattgaccttggc-3′, R 5′-caag
gtgctggctgagtagatc-3′;
human MMP-9, F 5′-ttggcgacaagaagtgg-3′, R 5′-gccattc
acgtcgtccttat-3′.
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Esophageal cancer cells and hUCMSCs were co-cultured
by transwell system for 48 hours. Then, hUCMSCs were
collected. Equal amounts of whole cell lysates were
resolved by SDS-PAGE and electrotransferred on a
PVDF membrane. Primary antibody [anti-human survi-
vin (1:2000; Cell Signaling, USA); anti-human Bcl-2,
anti-human BAX and anti-human β-actin (1:1000; Dingguo,
China), anti-human MMP-2, anti-human MMP-9 (1:1000;
proteintech, USA)] incubation was carried out overnight
at 4°C. The immunoreactive signals were detected with
an enhanced chemiluminescence kit (Millipore). Quan-
titative analyses were performed using a Gel Doc 2000
scanner system and Quantity One image analysis soft-
ware (Bio-Rad).
Statistical analysis
All statistical analyses were performed using SPSS 13.0
software package. Statistical significance was assessed by
comparing mean values (means ± SD). The two-tailed
student’s t-test was used to test the probability of signifi-
cant differences between samples. The significance level
was set at P < 0.05.
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